Related Experiment Video

Updated: Apr 25, 2026

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.6K

Targeting CDKN3 in cervical cancer

Jaime Berumen1, Ana María Espinosa, Ingrid Medina

  • 1Universidad Nacional Autonoma de Mexico, Facultad de Medicina, Unidad de Medicina Experimental, Unidad de Medicina Genómica , Dr. Balmis 148 Z.C. 06726, Mexico City , Mexico +52 55 27892000 Ext. 1281 ; +52 55 27892000 Ext. 1280 ; jaimeberumen@hotmail.com , jaimeberumen@yahoo.com.mx.

Expert Opinion on Therapeutic Targets
|August 26, 2014
PubMed
Abstract

Insights

The cyclin-dependent kinase inhibitor 3 gene (CDKN3) is upregulated in cervical cancer (CC), correlating with poor survival. Targeting CDKN3 shows promise for novel CC therapies and patient selection.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The cyclin-dependent kinase inhibitor 3 gene (CDKN3) plays a role in mitosis.
  • CDKN3 is upregulated in cervical cancer (CC) and linked to reduced patient survival.
  • CDKN3 represents a potential therapeutic target in CC, similar to its role in other cancers.

Purpose of the Study:

  • To review evidence on CDKN3 upregulation in CC.
  • To evaluate CDKN3's role in mitosis, cell cycle, and proliferation.
  • To assess CDKN3 as a prognostic marker and therapeutic target for CC.

Main Methods:

  • Literature review of studies on CDKN3 in CC.
  • Analysis of CDKN3's function in cell cycle regulation and proliferation.
  • Examination of CDKN3 targeting using small interfering RNA (siRNA) in cancer cell lines.

Main Results:

  • CDKN3 upregulation is associated with poor survival in CC patients.
  • CDKN3 targeting with siRNA suppresses proliferation in CC and other cancer cell lines.
  • Evidence supports CDKN3's role in cell proliferation and mitosis.

Conclusions:

  • CDKN3 may serve as a prognostic marker for CC patient survival.
  • CDKN3 is a potential target for developing specific small molecule drugs for CC treatment.
  • Targeting CDKN3 could aid in selecting CC patients for chemotherapy or targeted therapy.
Keywords:
cancer treatmentcancer-targeting genescervical cancercyclin-dependent kinase inhibitor 3 genegene expressionhuman papilloma virusmicroarraysmitosis

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

6.8K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

2.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.8K